Major Events - Shanghai Zhiyuan Hengyue Technology completed the tender offer for Shangwei New Materials, acquiring 58.6232% of the shares, with trading resuming on October 30, 2025 [4] - Peking University Pharmaceutical's chairman and president Xu Xiren has been detained for criminal investigation, but the company's control and operations remain normal [5] - China Unicom's chairman Chen Zhongyue resigned due to work adjustments, effective October 29, 2025 [6][7] - CITIC Financial Assets increased its stake in Hangyang Co., Ltd. to 5% through a block trade, reflecting confidence in the company's future [8] - Haoshi Electromechanical's subsidiary plans to invest 232 million yuan in a high-end equipment intelligent manufacturing project [9] - Zhejiang Xiantong's second shareholder Li Qifu plans to invest 130 million yuan in Qiteng Robotics to enhance production capacity [10] - Qianjiang Biochemical's subsidiary has completed a project for bio-pesticide production, with an annual capacity of 3,261 tons [11] - Dongni Electronics will face risk warnings and a one-day suspension due to an administrative penalty [12] - Jindao Technology signed a strategic cooperation agreement with Hangcha Group to develop robotic joint modules [14] Performance Overview - Kweichow Moutai reported Q3 net profit of 19.224 billion yuan, a 0.48% increase year-on-year, with total revenue of 39.064 billion yuan [15] - Huibai New Materials achieved a Q3 net profit of 27.1307 million yuan, a 3066.26% increase year-on-year, with revenue growth of 49.59% [16] - Zangzi Island reported a Q3 net loss of 42.5226 million yuan, with revenue down 19.92% [17] - OFILM reported a Q3 net profit of 40.8235 million yuan, a 411.91% increase year-on-year, with revenue growth of 21.15% [18] - China Rare Earth's Q3 net profit was 30.4752 million yuan, down 26.43% year-on-year, with revenue declining 22.4% [19] - Tianqi Lithium reported a Q3 net profit of 95.4855 million yuan, turning a profit after previous losses [20] - New Yisheng's Q3 net profit was 2.385 billion yuan, a 205.38% increase year-on-year, driven by AI-related sales growth [21] - Industrial Fulian's Q3 net profit increased by 49% year-on-year [22] - CICC's Q3 net profit grew by 130% year-on-year [23] - Tianpu Co., Ltd. reported a Q3 net profit increase of 33% [24] - BlueFocus reported a Q3 net profit of 99.2389 million yuan, a 265.47% increase year-on-year [25] - Ningshui Group's Q3 net profit was 21.7388 million yuan, a 347.57% increase year-on-year [26] - Shoukai Co. reported a Q3 net loss of 3.105 billion yuan [27] - Xiamen Xiangyu's Q3 net profit was 601 million yuan, a 443.17% increase year-on-year [29] - Huaneng Intelligent reported a Q3 net loss of 53.8408 million yuan, a significant decline [30] - Zhongjin Gold's Q3 net profit increased by 39.18% year-on-year [31] - Shandong Gold's Q3 net profit increased by 92% year-on-year [32] - Yahua Group's Q3 net profit was 198 million yuan, a 278.06% increase year-on-year [33] - Western Gold's Q3 net profit increased by 168% year-on-year [34] - Laobai Gan Liquor reported a 28% decline in net profit for the first three quarters [35] - Kaiying Network's Q3 net profit was 633 million yuan, a 34.51% increase year-on-year [36] - Tongchen Beijian reported a Q3 net profit of 171 million yuan, turning a profit from previous losses [37] - Nanshan Holdings' Q3 net profit increased by 203.51% year-on-year [38] - China Merchants Bank's Q3 net profit was 38.842 billion yuan, a 1.04% increase year-on-year [39] - Huahong Technology's Q3 net profit increased by 7111% year-on-year [40] - Fangda Special Steel's Q3 net profit increased by 1368.1% year-on-year [41] Shareholding Changes - WuXi AppTec's controlling shareholder plans to reduce its stake by up to 2% [43] - Hecai Technology's major shareholder Bosch China plans to reduce its stake by up to 3% [44] Major Contracts - China Electric Power Construction signed a contract worth 6.568 billion yuan for a hospital project in Peru [45] - Lanshi Heavy Industry signed a significant contract in the nuclear energy sector worth 581 million yuan [46] - Guoke Military Industry's subsidiary signed a major sales contract worth 466 million yuan [48]

二、项目对公司的影响 浙江钱江生物化学股份有限公司 关于生物农药原药及制剂退区入园搬迁项目投产的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、项目基本情况 浙江钱江生物化学股份有限公司（以下简称"公司"）于 2023 年 2 月 27 日 召开的十届董事会 2023 年第一次临时会议，审议通过了《关于全资子公司建设 钱江生化生物农药原药及制剂退区入园搬迁项目的议案》，公司董事会同意由公 司全资子公司浙江启潮生物科技有限公司（以下简称"启潮生物"）实施建设本 项目，授权公司及启潮生物经营层全权开展本项目的建设工作。具体内容详见公 司临 2023-006 公告。 2025 年 10 月 29 日，公司接启潮生物通知，经过前期的项目建设，生物农 药原药及制剂退区入园搬迁项目已具备试运营条件。本项目主要从事赤霉酸系列 等原药及制剂及新型环保型农药制剂产品的研发及生产，通过采用先进的技术设 备，结合公司生产工艺的优化，将大幅度地提升公司的生产技术水平，达产后具 备年产规模 3,261 吨原药制剂和 2,000 万片片 ...

Core Viewpoint - The company announced that its wholly-owned subsidiary, Qichao Biotechnology, has completed the construction of a biopesticide raw material and formulation relocation project, which is now ready for trial operation [1] Group 1: Project Details - The project focuses on the research and production of gibberellin series raw materials and formulations, as well as new environmentally friendly pesticide formulation products [1] - Upon reaching full production capacity, the project is expected to achieve an annual output of 3,261 tons of raw material formulations and 20 million tablets [1]

Core Viewpoint - Qianjiang Biochemical (600796) announced that its wholly-owned subsidiary, Qichao Biotechnology, has completed the construction of a biopesticide raw material and formulation relocation project, which is now ready for trial operation [1] Group 1: Project Details - The project focuses on the research and production of gibberellin series raw materials and formulations, as well as new environmentally friendly pesticide formulations [1] - Advanced technology and optimized production processes will significantly enhance the company's production capabilities [1] Group 2: Production Capacity - Upon reaching full production capacity, the project is expected to achieve an annual output of 3,261 tons of raw material formulations and 20 million tablets [1]

Core Viewpoint - Qianjiang Biochemical (600796.SH) announced that its wholly-owned subsidiary, Zhejiang Qichao Biotechnology Co., Ltd. (referred to as "Qichao Biotechnology"), has completed the preliminary construction of the biopesticide raw materials and formulations relocation project, which is now ready for trial operation [1] Group 1 - The project focuses on the research and production of gibberellin series raw materials and formulations, as well as new environmentally friendly pesticide formulations [1] - The implementation of advanced technology and optimization of production processes will significantly enhance the company's production technology level [1] - Upon reaching full production capacity, the project is expected to achieve an annual production capacity of 3,261 tons of raw materials and 20 million tablets [1]

格隆汇10月28日丨钱江生化(600796.SH)发布三季报，2025年前三季度实现营业总收入11.99亿元，同比 下降7.83%；归属母公司股东净利润1.51亿元，同比增长17.49%；基本每股收益为0.17元。 ...

Company Performance - Qianjiang Biochemical reported a revenue of approximately 1.199 billion yuan for the first three quarters of 2025, representing a year-on-year decrease of 7.83% [1] - The net profit attributable to shareholders of the listed company was approximately 151 million yuan, showing a year-on-year increase of 17.49% [1] Market Overview - As of the report, Qianjiang Biochemical has a market capitalization of 5.3 billion yuan [2] - The A-share market has surpassed 4,000 points, indicating a significant market resurgence after a decade of stagnation, with a new "slow bull" market pattern emerging [2]

证券代码：600796 证券简称：钱江生化 浙江钱江生物化学股份有限公司 2025 年第三季度报告 浙江钱江生物化学股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 | 量净额 | | | | | | --- | --- | --- | --- | --- | | 基本每股收益（元/股） | 0.05 | 0 | 0.17 | 13.33 | | 稀释每股收益（元/股） | 0.05 | 0 | 0.17 | 13.33 | | 加权平均净资产收益率 （%） | 1.34 | 减少 0.13 个百分点 | 4.53 | 增加 0.5 个百 分点 | | | | | ...

浙江钱江生物化学股份有限公司 Zhejiang Qianjiang Biochemical Co., Ltd 二零二五年第四次临时股东大会会议资料 浙江钱江生物化学股份有限公司 2025 年第四次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证大会 的顺利进行，根据《公司章程》、公司《股东大会议事规则》等相关法律法规的要求， 特制定本年度股东大会会议须知。 一、董事会以维护股东的合法权益、确保大会正常秩序和议事效率为原则，认真 履行《公司章程》中规定的职责。 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，务请出席 大会的股东或股东代理人（以下统称"股东"）及相关人员准时到达会场签到确认参 会资格。股东参会登记当天没有通过电话、邮件或传真方式登记的，不在签到表上登 记签到的，或会议正式开始后没有统计在会议公布股权数之内的股东或股东代理人， 不参加表决和发言。 2025 年 10 月 31 日 | | | | 2025年第四次临时股东大会会议须知 2 | | --- | | 2025年第四次临时股东大会会议议程 3 | | 2025年第四次临时股东大会会议议 ...

Core Points - Zhejiang Qianjiang Biochemical Co., Ltd. (referred to as "Qianjiang Biochemical") held its 10th Board of Directors' sixth extraordinary meeting on October 15, 2023, where several important resolutions were passed, including the expansion of business scope, the cancellation of the supervisory board, and amendments to the Articles of Association and its attachments [1]. Group 1 - Qianjiang Biochemical will absorb and merge its wholly-owned subsidiary Haining Jiahui Property Management Co., Ltd., inheriting all assets, liabilities, businesses, and personnel from the subsidiary. The company will expand its business scope to include "property management; non-residential real estate leasing," while other business areas will remain unchanged [2]. - The company plans to amend its Articles of Association and related documents, eliminating the supervisory board and transferring its functions to the audit committee of the board of directors. The positions of supervisors Yu Qiang and Zhu Xiaofang will be terminated, and relevant supervisory rules will be abolished [3]. Group 2 - The rules for shareholder meetings and board meetings have been revised. Changes in the shareholder meeting rules include adjustments to the purpose, powers, conditions for convening, and proposal requirements. The board meeting rules have been modified regarding director nominations, responsibilities, board composition, powers, and meeting procedures [4]. - These measures aim to optimize the corporate governance structure, adapt to business development needs, and enhance operational efficiency and competitiveness. The company will proceed with the necessary business registration procedures after the resolutions are approved at the shareholders' meeting, with the final amendments subject to approval by the business registration management department [4].